My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 469

    1.

    Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.

    Iozzo P, Hallsten K, Oikonen V, Virtanen KA, Parkkola R, Kemppainen J, Solin O, Lonnqvist F, Ferrannini E, Knuuti J, Nuutila P.

    Diabetes Care. 2003 Jul;26(7):2069-74.PMID: 12832315 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.

    Virtanen KA, Hällsten K, Parkkola R, Janatuinen T, Lönnqvist F, Viljanen T, Rönnemaa T, Knuuti J, Huupponen R, Lönnroth P, Nuutila P.

    Diabetes. 2003 Feb;52(2):283-90.PMID: 12540598 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin.

    Viljanen AP, Virtanen KA, Järvisalo MJ, Hällsten K, Parkkola R, Rönnemaa T, Lönnqvist F, Iozzo P, Ferrannini E, Nuutila P.

    J Clin Endocrinol Metab. 2005 Dec;90(12):6523-8. Epub 2005 Sep 27.PMID: 16189256 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus.

    Borra R, Lautamäki R, Parkkola R, Komu M, Sijens PE, Hällsten K, Bergman J, Iozzo P, Nuutila P.

    Metabolism. 2008 Oct;57(10):1445-51.PMID: 18803951 [PubMed - indexed for MEDLINE]Related articles

    5.

    Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.

    Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, Yudkin JS, Ferrannini E.

    Diabetes Care. 2004 Jun;27(6):1349-57.PMID: 15161787 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.

    Juurinen L, Kotronen A, Granér M, Yki-Järvinen H.

    J Clin Endocrinol Metab. 2008 Jan;93(1):118-24. Epub 2007 Oct 23.PMID: 17956948 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.

    Basu R, Shah P, Basu A, Norby B, Dicke B, Chandramouli V, Cohen O, Landau BR, Rizza RA.

    Diabetes. 2008 Jan;57(1):24-31. Epub 2007 Oct 3.PMID: 17914032 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.

    Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H.

    Diabetes. 2004 Aug;53(8):2169-76.PMID: 15277403 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.

    Karlsson HK, Hällsten K, Björnholm M, Tsuchida H, Chibalin AV, Virtanen KA, Heinonen OJ, Lönnqvist F, Nuutila P, Zierath JR.

    Diabetes. 2005 May;54(5):1459-67.PMID: 15855334 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.

    Hällsten K, Virtanen KA, Lönnqvist F, Janatuinen T, Turiceanu M, Rönnemaa T, Viikari J, Lehtimäki T, Knuuti J, Nuutila P.

    Diabet Med. 2004 Dec;21(12):1280-7.PMID: 15569129 [PubMed - indexed for MEDLINE]Related articles

    11.

    Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.

    Hällsten K, Virtanen KA, Lönnqvist F, Sipilä H, Oksanen A, Viljanen T, Rönnemaa T, Viikari J, Knuuti J, Nuutila P.

    Diabetes. 2002 Dec;51(12):3479-85.PMID: 12453903 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue.

    Abbasi F, Kamath V, Rizvi AA, Carantoni M, Chen YD, Reaven GM.

    Diabetes Care. 1997 Dec;20(12):1863-9.PMID: 9405908 [PubMed - indexed for MEDLINE]Related articles

    13.

    Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

    Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Insulin-mediated hepatic glucose uptake is impaired in type 2 diabetes: evidence for a relationship with glycemic control.

    Iozzo P, Hallsten K, Oikonen V, Virtanen KA, Kemppainen J, Solin O, Ferrannini E, Knuuti J, Nuutila P.

    J Clin Endocrinol Metab. 2003 May;88(5):2055-60.PMID: 12727954 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

    Cusi K, Consoli A, DeFronzo RA.

    J Clin Endocrinol Metab. 1996 Nov;81(11):4059-67.PMID: 8923861 [PubMed - indexed for MEDLINE]Related articles

    16.

    Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study.

    Lautamäki R, Airaksinen KE, Seppänen M, Toikka J, Luotolahti M, Ball E, Borra R, Härkönen R, Iozzo P, Stewart M, Knuuti J, Nuutila P.

    Diabetes. 2005 Sep;54(9):2787-94.PMID: 16123370 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

    Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

    Clin Ther. 2005 Sep;27(9):1383-91.PMID: 16291411 [PubMed - indexed for MEDLINE]Related articles

    18.

    Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.

    Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE.

    Diabetes Care. 2003 Jun;26(6):1685-90.PMID: 12766094 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.

    Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E, Cersosimo E, DeFronzo RA.

    Diabetes Care. 2006 Nov;29(11):2371-7.PMID: 17065670 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes.

    Gastaldelli A, Miyazaki Y, Pettiti M, Santini E, Ciociaro D, Defronzo RA, Ferrannini E.

    J Clin Endocrinol Metab. 2006 Mar;91(3):806-12. Epub 2005 Dec 13.PMID: 16352689 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity